Use of the interleukin-2 fusion protein, DAB389IL-2, for the treatment of psoriasis

Dermatologic Therapy

Volumn 5, Issue , 1998, Pages 48-63

  Gottlieb, Alice Bendix ^a   Bacha, Patricia ^a   Parker, Karen ^a   Strand, Vibeke ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIN; FILAGGRIN; GAMMA INTERFERON; HYBRID PROTEIN; INTERLEUKIN 2 RECEPTOR;

CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; DRUG DISPOSITION; DRUG SAFETY; GENE EXPRESSION; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PSORIASIS; RECEPTOR BINDING; REVIEW;

EID: 0031954067     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Mansbridge JN, Knapp AM. Changes in keratinocyte maturation during wound healing. J Invest Dermatol 1987: 89: 253-263.
2. Gottlieb AB, Chang CK, Posnett DN, Fanelli B, Tam JP. Detection of transforming growth factor alpha in normal, malignant, and hyperproliferative human keratinocytes. J Exp Med 1988: 167: 670-675.
3. Krueger JG, Krane JF, Carter DM, Gottlieb AB. Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. J Invest Dermatol 1990: 94: 135S-140S.
4. Krane JF, Gottlieb AB, Carter DM, Krueger JG. The insulin-like growth factor I receptor is overexpressed in psoriatic epidermis, but is differently regulated from epidermal growth factor receptor. J Exp Med 1992: 175: 1081-1090.
5. Nickloff BJ. The cytokine network in psoriasis. Arch Dermatol 1991: 127: 871-884.
6. Weinstein GD. Methotrexate. Intern Med 1977: 86: 199-204.
7. Krueger JG, Wolfe JT, Nabeya RT et al. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med 1995: 182: 2057-2068.
8. 389IL-2) suggests a primary immune, but not a keratinocyte, pathogenic basis. Nature Med 1995: 1: 442-447.
9. Vallat VP, Gilleaudeau P, Battat L et al. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: A possible cellular basis for remittive therapy. J Exp Med 1994: 180: 283-296.
10. Gerritsen MJP, Boezeman JBM, Van Vlijmen-Willems IMJJ, Van de Kerkhof PCM. The effect of tacalcitol (1,2(OH)2D3 on cutaneous inflammation, epidermal proliferation and keratinization in psoriasis: A placebo-controlled, double-blind study. Br J Dermatol 1994: 131: 57-63.
11. Krueger JG, Gottlieb AB. Cellular signaling in psoriasis: Growth factors, cytokines, and eicosanoids. In: Dubertret L, ed. Psoriasis. Brescia, Italy: ISED Press, 1994: 18-28.
12. Gottlieb AB, Lifshitz B, Fu SM, Staiano-Coico L, Wang CY, Carter DM. Expression of HLA-DR molecules by keratinocytes and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J Exp Med 1986: 164: 1013-1028.
13. Gottlieb AB. Immunologic mechanisms in psoriasis. J Am Acad Dermatol 1988: 18: 1376-1380.
14. Gottlieb AB, Luster AD, Posnett DN, Carter DM. Detection of a gamma-interferon-induced protein (IP-10) in psoriatic plaques. J Exp Med 1988: 168: 941-948.
15. Gottlieb AB, Krueger JG. HLA region genes and immune activation in the pathogenesis of psoriasis. Arch Dermatol 1990: 126: 1083-1086.
16. Gottlieb AB, Krueger JG. The role of activated T lymphocytes in the pathogenesis of psoriasis. In: Dubertret L, ed. Psoriasis. Brescia, Italy: ISED Press, 1994: 63-71.
17. Baker BS, Griffiths CEM, Lambert S et al. The effects of cyclosporin A on T lymphocyte and dendritic cell subpopulations in psoriasis. Br J Dermatol 1987: 116: 503-510.
18. Livden JK, Nilsen R, Bjerke JR, Matre R. In situ localization of interferons in psoriatic lesions. Arch Dermatol Res 1989: 281: 392-397.
19. Cooper KD. Psoriasis: leukocytes and cytokines. Dermatol Clin 1990: 8: 737-745.
20. Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematous-like syndrome. Br Med J 1996: 312: 169-172.
21. Ellis CN, Fradin MS, Messana MMJM et al. Cyclosporine for plaque-type psoriasis. Results of a multi-dose, double-blind trial. N Engl J Med 1991: 324: 277-284.
22. Bos JD, VanJoost T, Powles AV, Meinardi HM, Fry L. Use of cyclosporin in psoriasis. Lancet 1989: 23: 1500-1989.
23. Gottlieb AB, Grossman RM, Khandke L et al. Studies of the effect of cyclosporine in psoriasis in vivo: Combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol 1992: 98: 302-309.
24. 1 independent of effects of transforming growth factor-α/epidermal growth factor receptor pathways. Arch Dermatol 1991: 127: 1127-1179.
25. Lu I, Gilleaudeau P, McLane JA et al. Modulation of epidermal differentiation, tissue inflammation, and T-lymphocyte infiltration in psoriatic plaques by topical calcitrol. J Cutan Pathol 1996: 23: 419-434.
26. Gottlieb SL, Hayes E, Gilleaudeau P, Cardinale I, Gottlieb AB, Krueger JG. Etretinate promotes keratinocyte terminal differentiation and reduces T-cell infiltration in psoriatic epidermis. J Cutan Pathol 1996: 23: 404-418.
27. Takeshita T, Asao H, Ohtani K et al. Cloning of the γ chain of the IL-2 receptor. Science 1992: 257: 379.
28. Weismann AM, Harford JB, Svetlik PB et al. Only high-affinity receptors for interleukin 2 mediate internalization of ligand. Proc Natl Acad Sci U S A 1986: 83: 1463-1466.
29. Siegel JP, Sharon M, Smith PL, Leonard WJ. The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK and proliferative activities. Science 1987: 238: 75-78.
30. Tsudo M, Goldman CK, Bongiovanni KF et al. The p75 peptide is the receptor for interleukin-2 expressed on large granular lymphocytes and is responsible for the interleukin-2 activation of these cells. Proc Natl Acad Sci U S A 1987: 84: 5394-5398.
31. Lowenthal JW, Macdonald HR, Iacopetta BJ. Intracellular pathway of interleukin 2 following receptor-mediated endocytosis. Eur J Immunol 1986: 16: 1461-1463.
32. Waldmann TA. The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 1986: 232: 727-731.
33. Waldmann TA, Goldman CK, Robb RJ et al. Expression of interleukin 2 receptors on activated human B cells. J Exp Med 1984: 160: 1460-1466.
34. 389IL-2) for the treatment of interleukin-2 receptor (IL-2R) expressing hematologic neoplasms. Blood 1995: 86 (Suppl 1): 274A.
35. 389IL-2, in rheumatoid arthritis. Arthritis Rheum 1995: 36: 130.
36. 389IL-2 in HIV infection. October 1994, 34th ICAAC Conference, Orlando, Florida.
37. Fredrickson T, Peterson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978: 157: 238-244.